Clinical Trial

Effects of Resistance Training on Women With Functional Hypothalamic Amenorrhea

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 29, 2026 (before its estimated July 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
Functional hypothalamic amenorrhea (FHA) is a condition where women lose their menstrual periods, typically due to a combination of stress and insufficient calorie intake to fuel their daily physical activity (low energy availability). Standard medical advice often requires these women to completely stop exercising to recover their energy balance and hormones. However, this "complete rest" approach can cause severe anxiety for active individuals and removes the necessary mechanical loading that keeps bones strong. This study evaluates the safety and effectiveness of an 8-week supervised resistance training (weightlifting) program as a realistic alternative treatment for active women with FHA. The researchers compare a group of women experiencing FHA to a control group of women with regular menstrual cycles. Over the 8 weeks, participants complete three moderate-intensity, full-body weightlifting sessions per week. The primary goal is to determine if women with FHA can successfully recover their menstrual cycles while continuing to lift weights. Additionally, the study monitors changes in muscle strength, jumping performance, body composition, resting heart rate, and psychological well-being. Ultimately, this study aims to provide healthcare providers and coaches with evidence-based strategies that allow female athletes to safely maintain their athletic identity and physical health during recovery.
Trial Details
NCT Number NCT07612735
Lead Sponsor Catholic University of Murcia
Conditions Amenorrhea, Functional Hypothalamic Amenorrhea (FHA), Low Energy Availability, Relative Energy Deficiency in Sport
Enrollment 28 participants
Start Date 2026-05-15
Primary Completion 2026-07-10 (estimated)
Study Completion 2026-07-25 (estimated)
Updated on ClinicalTrials.gov 2026-05-29